Your Patients’ Goals
Are Our Mission

“Three months after suffering a stroke, I started having spasticity. The muscles in my right arm tightened a lot and now I experience spasms. It affects movement and all sorts of things.”

Ruben, 40, adult upper limb spasticity patient

Over one million patients worldwide have experienced XEOMIN, and that number continues to grow 2*

At Merz, we understand the struggles and the unique needs of adult patients with upper limb spasticity (ULS), cervical dystonia, and blepharospasm.

XEOMIN® (incobotulinumtoxinA) was developed to help meet these unique needs

XEOMIN is well established in clinical practice both in the United States and around the world1,2

  • FDA approved in 2010 for use in the United States for cervical dystonia and blepharospasm in adults1
  • FDA approved in 2015 for use in the United States for upper limb spasticity in adults1
  • Approved in Europe for cervical dystonia and blepharospasm since 2005 and approved for post-stroke ULS in Europe since 20092
  • Approved in Canada for cervical dystonia, blepharospasm, and ULS since 20092
  • Has been used worldwide in 51 countries2
  • Over one million patients treated2*
  • Studied in clinical trials worldwide, which involved:
    • More than 400 adult patients with ULS2
      • Included both pretreated and treatment-naïve patients2
    • Nearly 600 patients with cervical dystonia2
      • The majority of these patients (87%) had been previously treated with another neurotoxin2
    • Nearly 400 patients with blepharospasm2
      • Almost all patients (99%) were previously treated with another neurotoxin therapy (as per the indication for XEOMIN in the treatment of blepharospasm)1✝

XEOMIN® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles and used to treat adults with:

  • upper limb spasticity
  • cervical dystonia
  • blepharospasm who were previously treated with onabotulinumtoxinA (Botox)

Learn about the XEOMIN state-of-the-art proprietary manufacturing process

*Patients used XEOMIN for other indications in addition to cervical dystonia, blepharospasm, and upper limb spasticity in adults.
Patients stopped taking Botox at least 10 weeks prior to starting the clinical trial.


  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2015.
  2. Data on file. Raleigh, NC: Merz North America, Inc.